CoChat
Sign Up
Cited by 25Opioid Use Disorder TreatmentPain Management and Opioid UsePharmacovigilance and Adverse Drug Reactions

Association between sublingual buprenorphine-naloxone exposure and dental disease

Open access
Etminan, Mahyar, Rezaeianzadeh, Ramin, Kezouh, Abbas, Aminzadeh, Kevin·2022·JAMA
DOI 10.1001/jama.2022.17485PMC PMC9856241
Open this paper in CoChat — free account

Abstract

This study examines the association of sublingual buprenorphine/naloxone and dental adverse events using the IQVIA health claims database.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2022.17485

Cites

1 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Clear evidence that TMB causes oral health problems has remained unavailable without more rigorous study designs such as randomized controlled trials.

    “Clear evidence for a causal effect of TMB has remained elusive to date in the absence of more rigorous study designs including randomized controlled trials.”

    From Oral Health Risks of Transmucosal Buprenorphine: Commentary on Tuan et al. and Zheng et al. (2025) · cites this paper as [8]

  • Etminan and colleagues' study had two main limitations: missing patient oral hygiene information and inability to determine prescription indication, which left open the possibility that some patients were treated for chronic pain without opioid use disorder.

    “Omission of patient oral hygiene information and inability to determine indication for prescriptions—exposing the possibility that some patients might have been treated for chronic pain without OUD—were noted as primary limitations.”

    From Oral Health Risks of Transmucosal Buprenorphine: Commentary on Tuan et al. and Zheng et al. (2025) · cites this paper as [8]

  • Etminan and colleagues' 2022 retrospective cohort study of more than 21,000 new users of sublingual buprenorphine/naloxone found greater oral health risks, including dental caries and tooth loss, compared with transdermal buprenorphine or oral naltrexone.

    “A 2022 a retrospective cohort study by Etminan and colleagues8 of over 21,000 new users of sublingual buprenorphine/naloxone demonstrated greater TMB-associated oral health risks, including dental caries and tooth loss, relative to transdermal buprenorphine or oral naltrexone.”

    From Oral Health Risks of Transmucosal Buprenorphine: Commentary on Tuan et al. and Zheng et al. (2025) · cites this paper as [8]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Etminan, M., Rezaeianzadeh, R., Kezouh, A., & Aminzadeh, K.
Affiliations
  • University of British Columbia (CA)
  • StatExpert Ltd, Laval, Quebec, Canada
  • University of Michigan (US)
Corresponding author
Etminan, Mahyar
Venue
JAMA
Publisher
American Medical Association (AMA)
Published
2022-12-13
Volume
328
Issue
22
Pages
2269
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
DOI
10.1001/jama.2022.17485
PMC
PMC9856241
OpenAlex
W36511932
Cited by
25
References
2
Citations by year
2026: 5 · 2025: 6 · 2024: 6 · 2023: 8
FWCI
4.40
Type
journal article
Language
en
Open access
Locations
  • JAMA (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Repositories DataBase (IRDB) (submittedVersion)
  • Nagasaki University's Academic Output SITE (Nagasaki University) (submittedVersion, cc-by-nc-nd)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
dental diseases, opioid analgesics, oral health, drug exposure
MeSH terms
Buprenorphine, Naloxone Drug Combination, Administration, Sublingual, Analgesics, Opioid, Humans, Stomatognathic Diseases, Narcotic Antagonists, Opioid-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review